Inova Genomes
Qiagen and Inova Translational Medicine Institute have announced the commercial launch of Inova Genomes, a database of ethnically, phenotypically, and ancestrally diverse whole genome sequence data from more than 2,800 families.
Qiagen will exclusively distribute the database, which contains more than 7,000 whole genomes. These datasets have been annoted with electronic health record information including bifurcation of normal vs. disease patients with high-level diagnosis as well as race, ethnicity/ancestry, and demographic information. The database also includes genotype, haplotype, longitudinal data, and pedigree information; while RNA-seq, miRNA, and methylation expression data are available for a subset of individuals. Therapeutic areas covered by the resource focus on pulmonary, gastrointestinal, genitourinary, cardiac, hematological, musculoskeletal and connective, endocrine and immunity, neoplasms, neurological disorders, microbial infection, dermatological, and ophthalmological systems.
Qiagen is offering standard and premium subscription options for Inova Genomes. A standard subscription provides access to VCF data annotated with detailed clinical information from de-identified electronic health records and is accessible only via Ingenuity Variant Analysis and CLC Biomedical Genomics Workbench. Premium subscriptions cover access to the full VCF, survey information on nutrition, environment, family history, stress and electronic health record data, BAM files, miRNA, RNA-seq and methylation data, and eligibility for access to biobanked samples and patient re-contact rights for trial recruitment.
Agilent SurePrint Gene Expression Microarrays
Agilent Technologies has updated its SurePrint gene expresssion microarrays for messenger RNA profiling in human, mouse, and rat models. The firm said the updates improve coding and noncoding content.
Updates to the SurePrint G3 Human v3 gene expression microarray were developed in collaboration with Ghent University for complete coverage of the LNCipedia 2.1 database to assay long noncoding RNA transcripts.
NeoGenomics NeoLab Assays
NeoGenomics launched its first 12 NeoLab liquid biopsy-based assays. The assays are based on next-generation sequencing and other molecular technologies and use cell-free circulating DNA and RNA found in blood plasma to identify molecular abnormalities in the bone marrow without the need for a bone marrow biopsy. The new assays include MDS/CMML profiling, AML profiling, FLT3 mutation analysis, NPM1 mutation analysis, IDH1/IDH2 mutation analysis, NRAS mutation analysis, KRAS mutation analysis, and translocations of PML-RARA, RUNX1-RUNX1T1, and Inv16.
For more recently launched products and services, please see the New Products page on our website.